0001048477-24-000010.txt : 20240212
0001048477-24-000010.hdr.sgml : 20240212
20240212172005
ACCESSION NUMBER: 0001048477-24-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240118
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 24621312
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
wk-form4_1707776385.xml
FORM 4
X0508
4
2024-01-18
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO STREET
SAN RAFAEL
CA
94901
1
0
0
0
1
Common Stock
2024-01-18
4
L
0
40
92.5975
A
419602
D
Common Stock
2024-02-08
4
M
0
15000
63.10
A
434602
D
Common Stock
2024-02-08
4
S
0
15000
89.77
D
419602
D
Common Stock
2024-02-09
4
M
0
15000
63.10
A
434602
D
Common Stock
2024-02-09
4
S
0
15000
88.28
D
419602
D
Common Stock
247333
I
Shares held by Jean-Jacques Bienaime Family Trust
Common Stock
100
I
Shares held as UTMA custodian for child 1
Common Stock
100
I
Shares held as UTMA custodian for child 2
Stock Option (Right to Buy Common Stock)
63.10
2024-02-08
4
M
0
15000
0
D
2014-12-04
2024-06-03
Common Stock
15000
146000
D
Stock Option (Right to Buy Common Stock)
63.10
2024-02-09
4
M
0
15000
0
D
2014-12-04
2024-06-03
Common Stock
15000
131000
D
The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 40 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
The price in column 4 is the weighted average price. The purchase price actually paid ranged from $92.595 to $92.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Tae Sang Yoo, Attorney-in-Fact
2024-02-12